Advertisement

Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection

  • Lourdes Domínguez-DomínguezEmail author
  • Otilia Bisbal
  • Mariano Matarranz
  • María Lagarde
  • Óscar Pinar
  • Asunción Hernando
  • Carlos Lumbreras
  • Rafael Rubio
  • Federico Pulido
Original Article
  • 52 Downloads

Abstract

Real-life cohorts have shown that the effectiveness of all-oral, direct-acting antivirals (DAA) for HCV treatment is > 90%. We aimed to explore the predictive factors of DAA success in HIV coinfection. This is an observational prospective study within the cohort “VIH-DOC”, Madrid, Spain. HIV/HCV-coinfected patients were included if they had been treated with DAAs between 9 January 2015 and 31 August 2016. The sustained virological response (SVR) was analysed in the intention-to-treat population. Binary logistic regression was used to study the impact of cirrhosis, anti-HCV therapy experience and the IL28B polymorphism on SVR, besides factors with a p value < 0.15 from the univariate analysis. DAA were prescribed to 423 patients. SVR was confirmed in 92.9%. The univariate analysis showed higher proportion of patients with SVR among those with DAA adherence ≥ 95% (difference + 10.3%, 95% CI 3.5–19.6) and a baseline CD4+ cell count ≥ 200/μL (difference + 14.7%, 95% CI 4.1–31.0). Logistic regression evinced that both DAA adherence and baseline CD4+ cell counts predicted the SVR (OR 3.9, 95% CI 1.8–8.8, and OR 5.2, 95% CI 1.9–13.9, respectively). Moreover, men who reported having sex with other men (MSM) were less likely to achieve SVR (OR 4.2, 95% CI 1.1–16.1). Among MSM, three of three patients without SVR were suspected to have experienced HCV reinfection. DAA for HCV in HIV-coinfected patients is highly effective. DAA adherence ≥ 95% and a baseline CD4+ count ≥ 200/μL predicted a higher probability of SVR. A lower rate of SVR was found in MSM, presumably due to a higher frequency of HCV reinfection.

Keywords

HIV/HCV coinfection Direct-acting antivirals Sustained virological response Treatment adherence HCV reinfection 

Notes

Acknowledgments

We thank our trained nurses (Adelina Barrio, Mercedes Morales, Laura Bermejo and Mireia Santacreu) for helping us with the clinical follow-up of the patients.

Funding

This work has no funding sources. This study was conducted as part of our routine work. All payments and honoraria reported by each author within her/his conflict of interest statement were received for activities outside the submitted work.

Compliance with ethical standards

Conflict of interest

- LDD has received payment for lectures from Abbvie, Gilead and Janssen, and she has received financial support for expert courses and congress by Merck Sharp and Dome, Gilead and Abbvie.

- OB has received payments for lectures from AbbVie, Merck Sharp and Dome and Janssen, and she has received scholarship for expert courses and congress by Merck Sharp and Dome, Janssen, Bristol-Myers-Squibb, Gilead and Abbvie. Her work is currently supported by the Spanish AIDS Research Network (RD16/0025/0017) that is included in the Spanish I+D+I Plan and is cofinanced by ISCIII-Subdirección General de Evaluación and European Funding for Regional Development (FEDER).

- MM reports honoraria for advisory boards from Abbvie and has received payment for lectures from AbbVie, Bristol-Myers-Squibb and Merck Sharp and Dome.

- ML reports honoraria as speaker in educational programs sponsored by Janssen, ViiV, Gilead, Bristol-Myers-Squibb, Merck Sharp and Dome and Abbvie; has received scholarship for expert courses by Merck Sharp and Dome, Janssen and Abbvie; and has received financial support for national and international HIV courses (registration and travel assistance).

- AH, OP and CL have no conflict of interest.

- RR reports grants and payment for lectures from Abbott, Boehringer Ingelheim, Bristol-Myers-Squibb, Gilead, Janssen, Merck Sharp and Dome and ViiV.

- FP has received honoraria for lectures and advisory boards from Abbvie, Gilead, Janssen and ViiV.

Ethical approval and informed consent

Patients signed an informed consent approved by the Ethics Committee belonging to the Biomedical Research Institute Imas12 (University Hospital 12 de Octubre) when included in the VIH-DOC cohort. This document allows clinical data recollection and analysis for observational study purposes.

Data were anonymised and managed according to the Good Clinical Practice Guidelines published by the World Medical Association Declaration of Helsinki.

Supplementary material

10096_2019_3488_MOESM1_ESM.doc (2.9 mb)
Online Resource 1 (DOC 2976 kb)
10096_2019_3488_MOESM2_ESM.doc (64 kb)
Online Resource 2 (DOC 64 kb)
10096_2019_3488_MOESM3_ESM.doc (40 kb)
Online Resource 3 (DOC 40 kb)
10096_2019_3488_MOESM4_ESM.doc (75 kb)
Online Resource 4 (DOC 75 kb)

References

  1. 1.
    Sulkowski MS, Naggie S, Lalezari J et al (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312:353–361CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Molina JM, Orkin C, Iser DM et al (2015) Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 385:1098–1106CrossRefGoogle Scholar
  3. 3.
    Wyles DL, Ruane PJ, Sulkowski MS et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:714–725CrossRefGoogle Scholar
  4. 4.
    Osinusi A, Townsend K, Kohli A et al (2015) Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 313:1232–1239CrossRefGoogle Scholar
  5. 5.
    Naggie S, Cooper C, Saag M et al (2015) Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:705–713CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Sulkowski MS, Eron JJ, Wyles D et al (2015) Ombitasvir, Paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1. A randomized trial. JAMA 313:1223–1231CrossRefGoogle Scholar
  7. 7.
    Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M (2017) Hepatitis C: efficacy and safety in real life. Liver Int 37(Suppl.1):26–32CrossRefGoogle Scholar
  8. 8.
    Milazzo L, Lai A, Calvi E et al (2017) Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 18:284–291CrossRefGoogle Scholar
  9. 9.
    Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA (2016) Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21242 hepatitis C genotype-1 patients. Antivir Ther.  https://doi.org/10.3851/IMP3117
  10. 10.
    Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA (2016) Comparative effectiveness of ledipasvir / sofosbuvir +/− ribavirin vs. ombitasvir / paritaprevir / ritonavir + dasabuvir +/− ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 44:400–410CrossRefGoogle Scholar
  11. 11.
    Del Bello D, Cha A, Sorbera M et al (2016) Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV. Clin Infect Dis 62:1497–1504CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Bhattacharya D, Belperio PS, Shahoumian TA et al (2017) Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis 64:1711–1720CrossRefGoogle Scholar
  13. 13.
    Piroth L, Wittkop L, Lacombe K et al (2017) Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients—French ANRS CO13 HEPAVIH cohort. J Hepatol 67:23–31CrossRefGoogle Scholar
  14. 14.
    Bischoff J, Mauss S, Cordes C et al (2018) Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med 19:299–307CrossRefGoogle Scholar
  15. 15.
    Berenguer J, Gil-Martin A, Jarrin I et al (2018) All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe findings. Hepatology 68:32–47CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Chen J, Florian J, Carter W et al (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144:1450–1455CrossRefGoogle Scholar
  17. 17.
    Yoshida EM, Sulkowski MS, Gane EJ et al (2015) Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 61:41–45CrossRefGoogle Scholar
  18. 18.
    Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T (2015) Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infect. Clin Infect Dis 60:608–610CrossRefGoogle Scholar
  19. 19.
    Burgess SV, Hussaini T, Yoshida EM (2016) Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: a concise review. Ann Hepatol 15:154–159Google Scholar
  20. 20.
    Mathurin P, Bataller R (2015) Trends in the management and burden of alcoholic liver disease. J Hepatol 62:S38–S46CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Vergara S, Macías J, Rivero A et al (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 45:969–974CrossRefGoogle Scholar
  22. 22.
    Macías J, Recio E, Vispo E et al (2008) Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 49:916–922CrossRefGoogle Scholar
  23. 23.
    Valerio L, Yazdanpanah Y, Poizot-Martin I et al (2008) Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 47:50–55CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Aldámiz-Echevarría T, González-García J, Von Wichmann MA et al (2015) Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients. Ann Hepatol 14:464–469Google Scholar
  25. 25.
    Pawlotsky JM (2014) New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 34:22–29CrossRefGoogle Scholar
  26. 26.
    Simmons B, Saleem J, Hill A, Riley RD, Cooke GS (2016) Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62:683–694CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ingiliz P, Martin TC, Rodger A et al (2017) HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 66:282–287CrossRefGoogle Scholar
  28. 28.
    Ingiliz P, Christensen S, Schewe K et al (2017) High incidence of HCV reinfection in HIV-positive MSM in the DAA Era. [Abstract PS9/5]. 16th European AIDS Conference. Milan, ItalyGoogle Scholar
  29. 29.
    Mira JA, Rivero A, Santos I et al (2007) Rapid Virological response at week 4 predicts sustained response to Pegylated interferon plus ribavirin among HIV/HCV Coinfected patients. Antivir Ther 12:523–529Google Scholar
  30. 30.
    Pineda JA, Morano-Amado LE, Granados R et al (2017) Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clin Microbiol Infect 23:409.e5–409.e8CrossRefGoogle Scholar
  31. 31.
    Buti M, Riveiro-Barciela M, Esteban R (2015) Management of direct-acting antiviral agent failures. J Hepatol 63:1511–1522CrossRefGoogle Scholar
  32. 32.
    Mason K, Dodd Z, Guyton M et al (2017) Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 47:202–208CrossRefGoogle Scholar
  33. 33.
    Townsend K, Petersen T, Gordon LA et al (2016) Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS 30:261–266CrossRefGoogle Scholar
  34. 34.
    Petersen T, Townsend K, Gordon LA et al (2016) High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int 10:310–319CrossRefGoogle Scholar
  35. 35.
    Puenpatom A, Hull M, McPheeters J, Schwebke K (2017) Treatment discontinuation, adherence, and real-world effectiveness among patients treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther.  https://doi.org/10.1007/s40121-017-0163-0
  36. 36.
    Sogni P, Gilbert C, Lacombe K et al (2016) All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort. Clin Infect Dis 63:763–770CrossRefGoogle Scholar
  37. 37.
    Montes ML, Olveira A, Ahumada A et al (2017) Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 31:1253–1260CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Lourdes Domínguez-Domínguez
    • 1
    Email author
  • Otilia Bisbal
    • 1
  • Mariano Matarranz
    • 1
  • María Lagarde
    • 1
  • Óscar Pinar
    • 2
  • Asunción Hernando
    • 1
    • 3
  • Carlos Lumbreras
    • 1
  • Rafael Rubio
    • 1
  • Federico Pulido
    • 1
  1. 1.HIV Unit, Internal Medicine DepartmentHospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12)MadridSpain
  2. 2.Pharmacy DepartmentHospital Universitario 12 de OctubreMadridSpain
  3. 3.Faculty of Biomedical and Health SciencesUniversidad Europea de MadridMadridSpain

Personalised recommendations